Physician profile
Matthew E Halpern
NPI 1538207600
$11,730.90
in general payments reported to CMS, 2019-2025
21 companies · $4,981 in 2025
The $4,981 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $128 · 2021: $253 · 2022: $226 · 2023: $389 · 2024: $5,553 · 2025: $4,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,838 · Food and Beverage: $1,048 · Travel and Lodging: $37.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,837.50 |
| Food and Beverage | $1,047.69 |
| Travel and Lodging | $37.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $10,167.10 | 2023-2025 | Libtayo |
| Abbvie INC. | $466.60 | 2019-2025 | |
| Janssen Biotech, INC. | $230.54 | 2021-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $116.82 | 2025 | |
| Amgen INC. | $108.03 | 2019-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $90.78 | 2019-2025 | |
| Leo Pharma INC. | $83.70 | 2022-2024 | Adbry |
| Incyte Corporation | $68.89 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.41 | 2022-2025 | Spevigo |
| Lilly USA, LLC | $49.62 | 2019-2024 | Taltz, Olumiant |
| Organogenesis INC. | $44.82 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $44.45 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.09 | 2019-2024 | Siliq |
| Ucb, INC. | $34.45 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $33.78 | 2022-2025 | Nemluvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.43 | 2024 | |
| Blueprint Medicines Corporation | $16.30 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.97 | 2023 | Ycanth |
| Kyowa Kirin, INC. | $14.77 | 2022 | |
| Genentech USA, INC. | $13.80 | 2020 | |
| Mission Pharmacal Company | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.